CD47-SIRPα axis in cancer therapy: Precise delivery of CD47-targeted therapeutics and design of anti-phagocytic drug delivery systems
As a "marker of self", CD47 is expressed on the surface of all cells in humans, mice, and other mammals to inhibit phagocytic destruction of normal cells through interacting with signal regulatory protein α (SIRPα) on the macrophages and dendritic cells and sending a "don't eat m...
Saved in:
Main Authors: | Junqiao Zhu (Author), Chengyuan Cai (Author), Jiaxin Li (Author), Jisheng Xiao (Author), Xiaopin Duan (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2022-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Overcoming immunotherapeutic resistance in PDAC: SIRPα-CD47 blockade
by: Abdullahi Alausa, et al.
Published: (2022) -
Targeting CD47/SIRPα as a therapeutic strategy, where we are and where we are headed
by: Tailong Qu, et al.
Published: (2022) -
Significance of CD47 expression in endometrial carcinoma
by: Nurhan Sahin, et al.
Published: (2022) -
Blocking CD47 Shows Superior Anti-tumor Therapeutic Effects of Bevacizumab in Gastric Cancer
by: Chenyang Shi, et al.
Published: (2022) -
The landscape overview of CD47-based immunotherapy for hematological malignancies
by: Hua Yang, et al.
Published: (2023)